The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has released its corporate governance statement for the financial year ending December 31, 2024. The statement, which has been approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations. This disclosure is part of Neuren’s commitment to transparency and accountability, potentially strengthening its position within the industry and providing assurance to stakeholders about its governance practices.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders and other serious neurological conditions.
YTD Price Performance: -11.60%
Average Trading Volume: 781
Technical Sentiment Signal: Buy
Current Market Cap: $970.1M
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.